158 related articles for article (PubMed ID: 26368810)
1. A Rescue Strategy for Handling Unevaluable Patients in Simon's Two Stage Design.
Belin L; Broët P; De Rycke Y
PLoS One; 2015; 10(9):e0137586. PubMed ID: 26368810
[TBL] [Abstract][Full Text] [Related]
2. A new adaptive design based on Simon's two-stage optimal design for phase II clinical trials.
Jin H; Wei Z
Contemp Clin Trials; 2012 Nov; 33(6):1255-60. PubMed ID: 22772088
[TBL] [Abstract][Full Text] [Related]
3. Optimal adaptive two-stage designs for early phase II clinical trials.
Shan G; Wilding GE; Hutson AD; Gerstenberger S
Stat Med; 2016 Apr; 35(8):1257-66. PubMed ID: 26526165
[TBL] [Abstract][Full Text] [Related]
4. Statistical inference for extended or shortened phase II studies based on Simon's two-stage designs.
Zhao J; Yu M; Feng XP
BMC Med Res Methodol; 2015 Jun; 15():48. PubMed ID: 26048655
[TBL] [Abstract][Full Text] [Related]
5. Minimax and admissible adaptive two-stage designs in phase II clinical trials.
Shan G; Zhang H; Jiang T
BMC Med Res Methodol; 2016 Aug; 16():90. PubMed ID: 27485595
[TBL] [Abstract][Full Text] [Related]
6. Approaches to handling data when a phase II trial deviates from the pre-specified Simon's two-stage design.
Wu Y; Shih WJ
Stat Med; 2008 Dec; 27(29):6190-208. PubMed ID: 18800338
[TBL] [Abstract][Full Text] [Related]
7. Methods for proper handling of overrunning and underrunning in phase II designs for oncology trials.
Englert S; Kieser M
Stat Med; 2015 Jun; 34(13):2128-37. PubMed ID: 25781860
[TBL] [Abstract][Full Text] [Related]
8. Optimal and minimax three-stage designs for phase II oncology clinical trials.
Chen K; Shan M
Contemp Clin Trials; 2008 Jan; 29(1):32-41. PubMed ID: 17544337
[TBL] [Abstract][Full Text] [Related]
9. Statistical issues for design and analysis of single-arm multi-stage phase II cancer clinical trials.
Jung SH
Contemp Clin Trials; 2015 May; 42():9-17. PubMed ID: 25749311
[TBL] [Abstract][Full Text] [Related]
10. How a new stratified adaptive phase II design could improve targeting population.
Tournoux-Facon C; De Rycke Y; Tubert-Bitter P
Stat Med; 2011 Jun; 30(13):1555-62. PubMed ID: 21432892
[TBL] [Abstract][Full Text] [Related]
11. Stochastically curtailed phase II clinical trials.
Ayanlowo AO; Redden DT
Stat Med; 2007 Mar; 26(7):1462-72. PubMed ID: 16900560
[TBL] [Abstract][Full Text] [Related]
12. Randomized phase II trials with a prospective control.
Jung SH
Stat Med; 2008 Feb; 27(4):568-83. PubMed ID: 17573688
[TBL] [Abstract][Full Text] [Related]
13. Optimal adaptive two-stage designs for phase II cancer clinical trials.
Englert S; Kieser M
Biom J; 2013 Nov; 55(6):955-68. PubMed ID: 23868324
[TBL] [Abstract][Full Text] [Related]
14. Balanced two-stage designs for phase II clinical trials.
Ye F; Shyr Y
Clin Trials; 2007; 4(5):514-24. PubMed ID: 17942467
[TBL] [Abstract][Full Text] [Related]
15. Adaptive two-stage designs in phase II clinical trials.
Banerjee A; Tsiatis AA
Stat Med; 2006 Oct; 25(19):3382-95. PubMed ID: 16479547
[TBL] [Abstract][Full Text] [Related]
16. A design of phase II cancer trials using total and complete response endpoints.
Lu Y; Jin H; Lamborn KR
Stat Med; 2005 Oct; 24(20):3155-70. PubMed ID: 16189806
[TBL] [Abstract][Full Text] [Related]
17. Two-stage k-sample designs for the ordered alternative problem.
Shan G; Hutson AD; Wilding GE
Pharm Stat; 2012; 11(4):287-94. PubMed ID: 22408050
[TBL] [Abstract][Full Text] [Related]
18. Alternative designs of phase II trials considering response and toxicity.
Jin H
Contemp Clin Trials; 2007 Jul; 28(4):525-31. PubMed ID: 17428744
[TBL] [Abstract][Full Text] [Related]
19. Modified Simon's minimax and optimal two-stage designs for single-arm phase II cancer clinical trials.
Kim J; Schell MJ
Oncotarget; 2019 Jul; 10(42):4255-4261. PubMed ID: 31303960
[TBL] [Abstract][Full Text] [Related]
20. An adjustment for patient heterogeneity in the design of two-stage phase II trials.
Sposto R; Gaynon PS
Stat Med; 2009 Sep; 28(20):2566-79. PubMed ID: 19521973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
